Elizabeth Jungman: Interpreter Of The FDA’s Policy Crystal Ball
Executive Summary
The Center for Drug Evaluation and Research’s policy guru must think about the future, along with the present, in her position as director of the Office of Regulatory Policy.
You may also be interested in...
US FDA’s Accelerated Approval Reforms Include Dispute Resolution For Withdrawals
Allowing decisions to be reviewed by higher management levels, rather than convening administrative hearings, could save time in the withdrawal process.
GOP Accelerated Approval Proposal Could Expand Eligibility For US FDA Pathway
The rival to House Energy and Commerce Committee Chair Frank Pallone’s bill would not set expiration dates for accelerated approvals.
US FDA Accelerated Approvals Could Expire Under New Legislation, But Big Loophole Included
The bill, some version of which is undoubtedly destined for the FDA user fee package, also would codify existing labeling guidance for products cleared through the pathway.